Market Closed -
Xetra
11:35:19 2024-06-04 am EDT
|
5-day change
|
1st Jan Change
|
166.4
EUR
|
-0.66%
|
|
-0.78%
|
+15.44%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
45,804
|
61,021
|
98,695
|
78,651
|
62,651
|
72,325
|
-
|
-
|
Enterprise Value (EV)
1 |
58,160
|
71,683
|
107,596
|
86,979
|
70,610
|
78,338
|
76,748
|
74,549
|
P/E ratio
|
34.7
x
|
30.7
x
|
32.3
x
|
23.6
x
|
22.2
x
|
24
x
|
20.4
x
|
18.3
x
|
Yield
|
1.23%
|
1%
|
0.81%
|
1.22%
|
1.53%
|
1.36%
|
1.47%
|
1.56%
|
Capitalization / Revenue
|
2.84
x
|
3.48
x
|
5.01
x
|
3.54
x
|
2.98
x
|
3.39
x
|
3.2
x
|
3.03
x
|
EV / Revenue
|
3.6
x
|
4.09
x
|
5.47
x
|
3.91
x
|
3.36
x
|
3.67
x
|
3.39
x
|
3.12
x
|
EV / EBITDA
|
13.3
x
|
13.8
x
|
17.6
x
|
12.7
x
|
12
x
|
13.2
x
|
11.6
x
|
10.3
x
|
EV / FCF
|
28.5
x
|
34.7
x
|
30.3
x
|
31.9
x
|
36.9
x
|
26.5
x
|
24.8
x
|
21.4
x
|
FCF Yield
|
3.51%
|
2.88%
|
3.3%
|
3.14%
|
2.71%
|
3.77%
|
4.03%
|
4.68%
|
Price to Book
|
2.56
x
|
3.59
x
|
4.63
x
|
3.03
x
|
2.35
x
|
2.51
x
|
2.3
x
|
2.11
x
|
Nbr of stocks (in thousands)
|
434,778
|
434,778
|
434,778
|
434,778
|
434,778
|
434,778
|
-
|
-
|
Reference price
2 |
105.4
|
140.4
|
227.0
|
180.9
|
144.1
|
166.4
|
166.4
|
166.4
|
Announcement Date
|
3/5/20
|
3/4/21
|
3/3/22
|
3/2/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
16,152
|
17,534
|
19,687
|
22,232
|
20,993
|
21,318
|
22,617
|
23,864
|
EBITDA
1 |
4,385
|
5,201
|
6,103
|
6,849
|
5,879
|
5,939
|
6,628
|
7,216
|
EBIT
1 |
2,120
|
2,985
|
4,179
|
4,474
|
3,609
|
4,033
|
4,661
|
5,189
|
Operating Margin
|
13.13%
|
17.02%
|
21.23%
|
20.12%
|
17.19%
|
18.92%
|
20.61%
|
21.74%
|
Earnings before Tax (EBT)
1 |
1,735
|
2,630
|
3,924
|
4,287
|
3,484
|
3,817
|
4,460
|
4,991
|
Net income
1 |
1,320
|
1,987
|
3,055
|
3,326
|
2,824
|
3,009
|
3,533
|
3,944
|
Net margin
|
8.17%
|
11.33%
|
15.52%
|
14.96%
|
13.45%
|
14.12%
|
15.62%
|
16.53%
|
EPS
2 |
3.040
|
4.570
|
7.030
|
7.650
|
6.490
|
6.941
|
8.162
|
9.084
|
Free Cash Flow
1 |
2,043
|
2,065
|
3,550
|
2,728
|
1,915
|
2,955
|
3,090
|
3,490
|
FCF margin
|
12.65%
|
11.78%
|
18.03%
|
12.27%
|
9.12%
|
13.86%
|
13.66%
|
14.62%
|
FCF Conversion (EBITDA)
|
46.6%
|
39.7%
|
58.17%
|
39.83%
|
32.57%
|
49.76%
|
46.62%
|
48.36%
|
FCF Conversion (Net income)
|
154.77%
|
103.9%
|
116.22%
|
82.02%
|
67.8%
|
98.2%
|
87.45%
|
88.47%
|
Dividend per Share
2 |
1.300
|
1.400
|
1.850
|
2.200
|
2.200
|
2.262
|
2.448
|
2.594
|
Announcement Date
|
3/5/20
|
3/4/21
|
3/3/22
|
3/2/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
8,489
|
5,213
|
5,198
|
5,568
|
5,806
|
5,660
|
5,293
|
5,302
|
5,173
|
5,225
|
5,120
|
5,262
|
5,415
|
5,547
|
-
|
-
|
EBITDA
1 |
2,256
|
1,464
|
1,629
|
1,782
|
1,810
|
1,628
|
1,587
|
1,553
|
1,446
|
1,293
|
1,454
|
1,428
|
1,513
|
1,695
|
-
|
-
|
EBIT
1 |
-
|
1,039
|
1,173
|
1,177
|
1,234
|
889.6
|
1,035
|
969
|
983
|
621
|
931
|
832.5
|
1,078
|
1,086
|
-
|
-
|
Operating Margin
|
-
|
19.93%
|
22.57%
|
21.14%
|
21.26%
|
15.72%
|
19.55%
|
18.28%
|
19%
|
11.89%
|
18.18%
|
15.82%
|
19.91%
|
19.58%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
991.9
|
1,139
|
1,122
|
1,187
|
839.1
|
1,012
|
894
|
937
|
641
|
899
|
807.4
|
1,053
|
1,063
|
-
|
-
|
Net income
1 |
-
|
802.1
|
880.4
|
867.1
|
923.2
|
655
|
796
|
704
|
739
|
586
|
694
|
699.3
|
823.8
|
874.8
|
-
|
-
|
Net margin
|
-
|
15.39%
|
16.94%
|
15.57%
|
15.9%
|
11.57%
|
15.04%
|
13.28%
|
14.29%
|
11.22%
|
13.55%
|
13.29%
|
15.21%
|
15.77%
|
-
|
-
|
EPS
2 |
1.720
|
1.840
|
2.020
|
1.990
|
2.120
|
1.510
|
1.830
|
1.620
|
1.700
|
1.340
|
1.600
|
1.603
|
1.908
|
2.018
|
-
|
-
|
Dividend per Share
2 |
-
|
1.850
|
-
|
-
|
-
|
2.200
|
-
|
-
|
-
|
2.200
|
-
|
0.5500
|
0.5500
|
0.5500
|
0.6000
|
0.6000
|
Announcement Date
|
8/6/20
|
3/3/22
|
5/12/22
|
8/4/22
|
11/10/22
|
3/2/23
|
5/11/23
|
8/3/23
|
11/9/23
|
3/7/24
|
5/15/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
12,357
|
10,662
|
8,902
|
8,328
|
7,959
|
6,013
|
4,422
|
2,224
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.818
x
|
2.05
x
|
1.459
x
|
1.216
x
|
1.354
x
|
1.012
x
|
0.6673
x
|
0.3081
x
|
Free Cash Flow
1 |
2,043
|
2,065
|
3,550
|
2,728
|
1,915
|
2,955
|
3,090
|
3,490
|
ROE (net income / shareholders' equity)
|
13.8%
|
16.7%
|
19.8%
|
18.5%
|
14%
|
13.7%
|
14.5%
|
14.6%
|
ROA (Net income/ Total Assets)
|
3.27%
|
4.64%
|
8.7%
|
9.31%
|
7.61%
|
6.9%
|
7.47%
|
7.82%
|
Assets
1 |
40,348
|
42,804
|
35,111
|
35,718
|
37,119
|
43,639
|
47,272
|
50,430
|
Book Value Per Share
2 |
41.10
|
39.10
|
49.10
|
59.60
|
61.40
|
66.30
|
72.20
|
78.80
|
Cash Flow per Share
2 |
6.580
|
8.000
|
10.60
|
9.800
|
8.700
|
10.90
|
11.50
|
12.60
|
Capex
1 |
813
|
1,413
|
1,066
|
1,531
|
2,024
|
1,879
|
1,963
|
1,988
|
Capex / Sales
|
5.03%
|
8.06%
|
5.41%
|
6.89%
|
9.64%
|
8.82%
|
8.68%
|
8.33%
|
Announcement Date
|
3/5/20
|
3/4/21
|
3/3/22
|
3/2/23
|
3/7/24
|
-
|
-
|
-
|
Last Close Price
166.4
EUR Average target price
184.8
EUR Spread / Average Target +11.10% Consensus |
1st Jan change
|
Capi.
|
---|
| +15.44% | 79.25B | | +14.26% | 9.15B | | -13.94% | 4.9B | | +48.58% | 4.46B | | +14.10% | 4.09B | | +19.66% | 2.49B | | -25.55% | 2.17B | | +18.39% | 2.1B | | -39.57% | 1.89B | | -0.50% | 1.64B |
Specialty & Advanced Pharmaceuticals
|